Because a high proportion of Tpex cells or less differentiated cells in the infusion product correlates with better persistence and antitumor activity in vivo, the addition of IL-15, which increases Tpex cells without further differentiation, could be applied to the ex vivo expansion protocol for adoptive T cell therapy for cancer patients. This evidence concerns the gene IL15 and cancer.